Roivant Sciences
| File:Roivantlogo.png | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2014 |
| Founder | Vivek Ramaswamy |
| Headquarters | |
| Website | www |
Roivant Sciences, Ltd. is a global biopharmaceutical company that focuses on helping patients by bringing new medications to market, through clinical development. Roivant uses mechanisms such as acquisitions, strategic alliances, collaborations and partnerships to accelerate the process.[1][2] The global company was founded in May 2014 by Vivek Ramaswamy and Lawrence Friedhoff[2][3][4] and is headquartered in Bermuda with offices and research facilities in New York City, Durham, NC and Switzerland.[5]
Roivant's mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by looking for promising drugs that are not being developed by other biopharmaceutical companies due to financial reasons or commercial alignments, and takes those drugs from where they were left off in late-stage clinical development and brings them through the final stages of approval.[6]
Therapeutic Areas
Roivant focuses on multiple therapeutic areas that have the biggest impact on those suffering from common and rare diseases. Roivant is developing solutions that include Axovant, Myovant, Enzyvant and Dermavant.[2] Roivant works on drugs that can be used with other treatments to ensure the best solution for patients.
Axovant is developing therapies for neurological diseases, including intepirdine for Alzheimer’s disease and Lewy body dementia.[3] Myovant, which is dedicated to women’s health and prostate cancer treatment programs, is working with Takeda Pharmaceuticals, to develop therapies for uterine fibroids, endometriosis, and prostate cancer.[7][8][9] Myovant has a worldwide license for the drug Relugolix,[10] which is a once-daily, orally administered drug for treatment. Enzyvant is working to develop therapies for rare diseases, including Farber disease.[11][12][13][14]
Axovant’s IPO was the largest biotech IPO in American history, raising $360 million.[1][3][15]
Partnerships & Community
Axovant, which develops dementia drugs, teamed up with ride-hailing service, Lyft, to transport patients in clinical Alzheimer's studies to the facilities in order to increase participation rates.[16]
Roivant's Axovant has also partnered with NFL broadcaster Solomon Wilcots on promoting an educational campaign about the importance of participation in Alzheimer's clinical trails, called "Huddle Up for New Alzheimer's Treatments."[17] Other retired NFL players that are part of the campaign include Jose Rose, Joey Harrington, Ron Pitts, Christian Fauria, Steve Tasker and Leigh Steinberg.[18]
African Americans are at least two times more likely to develop Alzheimer’s than white Americans, but they have been underrepresented in clinical research studies. In order to encourage more African American participation in clinical trials, Axovant is collaborating with African American Network Against Alzheimer’s to sponsor performances in several U.S cities of “Forget Me Not,” a play by Garrett Davis about an African American family coping with Alzheimer’s. (http://investors.axovant.com/investors/press-releases/2016/21-01-2016)
References
- ^ a b Vardi, Nathan. "Billionaire Andreas Halvorsen's Hedge Fund Backs Private Biotech Roivant Sciences". Forbes. Retrieved 2016-10-07.
- ^ a b c Vardi, Nathan. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 2016-10-07.
- ^ a b c Pollack, Andrew (2015-06-11). "Shares of Axovant, Alzheimer's Drug Developer, Surge on Trading Debut". The New York Times. ISSN 0362-4331. Retrieved 2016-10-07.
- ^ "Biotechnology Company Overview of Axovant Sciences Ltd". Bloomberg. Retrieved 2016-10-25.
- ^ "Roivant Contact Us".}
- ^ [ttp://roivant.com/#about "About Roivant"].}
- ^ "NASDAQ | SEC Filing". secfilings.nasdaq.com. Retrieved 2016-10-07.
- ^ Clifford, Rebecca. "Takeda forms new women's health and cancer company". PMLIVE. Retrieved 2016-10-24.
- ^ Taylor, Nick Paul. "Axovant founder, Takeda install ex-Medivation CMO at helm of PhIII-ready startup". Fierce Biotech. Retrieved 2016-10-07.
- ^ Boggs, Jennifer. "Roivant's Myovant Sciences files for $173M IPO to fund its phase III-ready asset". BioWorld. Retrieved 2016-10-07.
- ^ White, Victoria. "New company Enzyvant takes aim at Farber disease". Drug Target Review. Retrieved 2016-10-07.
- ^ Adams, Ben. "Roivant and Plexcera launch rare disease focused spinout". Fierce Biotech. Retrieved 2016-10-07.
- ^ Black, Andrew. "Enzyvant Sciences Created to Focus on Treatment of Farber Disease". Rare Disease Report. Retrieved 2016-10-07.
- ^ "New Developments in Farber Disease Research". Lysosomal Disease Network. Retrieved 2016-10-11.
- ^ "Axovant Sciences Ltd". United States Securities and Exchange Commission. Retrieved 2016-10-24.
- ^ "Companies Try New Ways to Attract Patients to Drug Trials".
- ^ "Retired NFL Players Call Greater Participation Alzheimers Clinical Trials Ambassadors Educational Events Memory Screenings".
- ^ "Leigh Steinberg Joins Retired NFL Players highlighting need Greater Participation Alzheimers Clinical Trials".
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |